Literature DB >> 8502820

A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy.

D M Wolf1, V C Jordan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8502820     DOI： 10.1007/978-3-642-84745-5_4

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN： 0080-0015


× No keyword cloud information.
  39 in total

1.  Profile of V. Craig Jordan.

Authors:  Sujata Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-16       Impact factor: 11.205

2.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

Review 3.  Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

4.  The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Authors:  V Craig Jordan; Ifeyinwa Obiorah; Ping Fan; Helen R Kim; Eric Ariazi; Heather Cunliffe; Hiltrud Brauch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

5.  Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.

Authors:  Eric A Ariazi; Heather E Cunliffe; Joan S Lewis-Wambi; Michael J Slifker; Amanda L Willis; Pilar Ramos; Coya Tapia; Helen R Kim; Smitha Yerrum; Catherine G N Sharma; Emmanuelle Nicolas; Yoganand Balagurunathan; Eric A Ross; V Craig Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-19       Impact factor: 11.205

6.  Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

Review 7.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

8.  Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

Authors:  I E Obiorah; V C Jordan
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

9.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

Review 10.  Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

Authors:  Joan S Lewis-Wambi; V Craig Jordan
Journal:  Breast Cancer Res       Date:  2009-05-29       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.